<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580784</url>
  </required_header>
  <id_info>
    <org_study_id>FAST feasibility in CU</org_study_id>
    <nct_id>NCT04580784</nct_id>
  </id_info>
  <brief_title>Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer</brief_title>
  <official_title>Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer: A Single Institution Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mona Salem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a prospective phase II study; Eligible patients will receive&#xD;
      hypofractionated Irradiation at a total dose of 28.5Gy in 5 once-weekly fractions of 5.7Gy in&#xD;
      5 weeks to the Whole Breast or chest wall with or without peripheral lymphatic irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast&#xD;
      surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks in Kasr&#xD;
      EL Aini Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cosmetic breast appearance</measure>
    <time_frame>six months</time_frame>
    <description>according to HARVARD cosmesis scale: 1 Excellent, 2Good, 3 Fair and 4 Poor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute radiation toxicity assessment</measure>
    <time_frame>six months</time_frame>
    <description>according to the RTOG acute toxicity scale: 0 No visible change, 1 faint/dull erythema, 2tender/ bright +- dry desquamation, 3 patchy moist desquamation, 4 conflueunt moist desquamation, pitting edema, 0 is the best and 4 is the worse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient quality of life assessment.</measure>
    <time_frame>six months</time_frame>
    <description>according to FACT-B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction.</measure>
    <time_frame>six months</time_frame>
    <description>according to FACIT-TS-PS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiotherapy Side Effect</condition>
  <arm_group>
    <arm_group_label>Hypofractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Weekly hypofractionation for early breast cancer</intervention_name>
    <description>Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks</description>
    <arm_group_label>Hypofractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven diagnosis of invasive breast adenocarcinoma.&#xD;
&#xD;
          2. Prior radical surgery (Modified Radical Mastectomy or Breast Conservative Surgery).&#xD;
&#xD;
          3. No macroscopic evidence of distant metastases at diagnosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior radiation to the thoracic region.&#xD;
&#xD;
          2. Pregnancy.&#xD;
&#xD;
          3. Patients with synchronous or prior malignancy.&#xD;
&#xD;
          4. Positive surgical margins.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Salem, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr El AiniH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mona M Salem, MSc</last_name>
    <phone>00201007731412</phone>
    <email>mona.m.salem@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr El AiniH</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean's office</last_name>
      <phone>002025729584</phone>
      <email>Dean@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Mona Salem</investigator_full_name>
    <investigator_title>Assistant Lecturer of clinical oncology</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Hypofractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

